1,3-OXAZOLIDINE OR 1,3-OXAZINANE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS

A heteroaromatic methyl cyclic amine derivative represented by formula (IA) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease,...

Full description

Saved in:
Bibliographic Details
Main Authors YUKO ARAKI, MASAHITO ABE, DAI NOZAWA, AYA FUTAMURA, HIROSHI OHTA, RYO SUZUKI
Format Patent
LanguageEnglish
Portuguese
Published 13.03.2017
Subjects
Online AccessGet full text

Cover

Loading…
Abstract A heteroaromatic methyl cyclic amine derivative represented by formula (IA) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of an orexin (OX) receptor antagonist activity.
AbstractList A heteroaromatic methyl cyclic amine derivative represented by formula (IA) or a pharmaceutically acceptable salt thereof is useful for treatment or prophylaxis of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's disease, eating disorder, cephalalgia, hemicrania, pain, digestive diseases, epilepsy, inflammation, immune-related diseases, endocrine-related diseases and hypertension, on the basis of an orexin (OX) receptor antagonist activity.
Author YUKO ARAKI
MASAHITO ABE
DAI NOZAWA
RYO SUZUKI
HIROSHI OHTA
AYA FUTAMURA
Author_xml – fullname: YUKO ARAKI
– fullname: MASAHITO ABE
– fullname: DAI NOZAWA
– fullname: AYA FUTAMURA
– fullname: HIROSHI OHTA
– fullname: RYO SUZUKI
BookMark eNrjYmDJy89L5WTwNNQx1vWPcIzy9_F08fRzVfAPUoAJefo5AgWc_X0D_EP9XIIVHIOBsq4Rnn4KQa7OrgEhQKWOfiGO7v5-nsEhwTwMrGmJOcWpvFCam0HBzTXE2UM3tSA_PrW4IDE5NS-1JD4gxMjCDIgMQkKMiVACANzeLt4
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate COMPOSTOS DE 1,3-OXAZOLIDINA OU 1,3-OXAZINANO COMO ANTAGONISTAS DO RECETOR DE OREXINA
ExternalDocumentID PT2862860TT
GroupedDBID EVB
ID FETCH-epo_espacenet_PT2862860TT3
IEDL.DBID EVB
IngestDate Fri Jul 19 12:48:57 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
Portuguese
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_PT2862860TT3
Notes Application Number: PT20130804876T
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170313&DB=EPODOC&CC=PT&NR=2862860T
ParticipantIDs epo_espacenet_PT2862860TT
PublicationCentury 2000
PublicationDate 20170313
PublicationDateYYYYMMDD 2017-03-13
PublicationDate_xml – month: 03
  year: 2017
  text: 20170313
  day: 13
PublicationDecade 2010
PublicationYear 2017
RelatedCompanies TAISHO PHARMACEUTICAL CO., LTD
RelatedCompanies_xml – name: TAISHO PHARMACEUTICAL CO., LTD
Score 3.0759056
Snippet A heteroaromatic methyl cyclic amine derivative represented by formula (IA) or a pharmaceutically acceptable salt thereof is useful for treatment or...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title 1,3-OXAZOLIDINE OR 1,3-OXAZINANE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170313&DB=EPODOC&locale=&CC=PT&NR=2862860T
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LTsMwzBoDATcYIMZLPaCeqFjXFLZDhbo0Y0UsqdYMVVxQ0qWCyzaxIn6fpFqBC9wiO7JsS7bjxHYALlUf5Qgh6bj-TDlI9LUf7AnPUUp0hVsIV3VMv_OY3oym6CHzswa81r0w1ZzQz2o4oraoXNt7Wfnr5c8lVlTVVq6u5ZsGLe6GPIjsdXbsmmnsnh0NApKwiGEb4yDhNp0E3Z7pwezwDdg0h2gzZZ88DUxPyvJ3QBnuwVaiac3LfWgsyxbs4PrftRZsj9fP3Xq5trzVAcTuleewLHxmj3EUU2KxiVWDYhpqAGbjhE1plFphqrEki6k1IZgkXG8NKQ_vGY1Tnh6CNSQcjxzN08u3-C8Jr5nn3hE054u5OgZLpx0mHZj5Ir9F0pey6HakFh_lPVH4xawN7T_JnPyDO4Vdo0dTZuV6Z9As3z_UuY67pbyoVPYFIKqCew
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LTsMwzBoDMW4wQIxnD6gnKtY1ZduhQl3ascCaVGuGKi5T07WCyzaxIn6fpFqBC9wiO7JsS7bjxHYArrM-ShFCwjDteWagpC_9YC-xjCxLOomZJ2bWVv3OAb0bTdFjbMc1eK16Yco5oZ_lcERpUam096L016ufSyyvrK1c34o3CVreD7nj6Zvs2FTT2C3dGzh-yDyGdYydkOt04nR6qgezzbdgu6tm86qD0_NA9aSsfgeU4T7shJLWojiA2qpoQgNX_641YTfYPHfL5cby1odAzBvLYLH7wsbEI9TX2ESrQIS6EoBZELIp9SLNjSTWjwnVJj72Qy63upS7D4ySiEdHoA19jkeG5Gn2Lf4s5BXz3DqG-mK5yE5Ak2mHSgfmdpJ2kbCFyDttIcVHaS_J7XzegtafZE7_wV1BY8SD8WxM6NMZ7CmdqpIr0zqHevH-kV3IGFyIy1J9X2NqhWg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=1%2C3-OXAZOLIDINE+OR+1%2C3-OXAZINANE+COMPOUNDS+AS+OREXIN+RECEPTOR+ANTAGONISTS&rft.inventor=YUKO+ARAKI&rft.inventor=MASAHITO+ABE&rft.inventor=DAI+NOZAWA&rft.inventor=AYA+FUTAMURA&rft.inventor=HIROSHI+OHTA&rft.inventor=RYO+SUZUKI&rft.date=2017-03-13&rft.externalDBID=T&rft.externalDocID=PT2862860TT